Page 30 - The Indian Optician Digital Edition November-December 2021

COOPERVISION SPECIALTY investigator of the study.

EYECARE INTRODUCES OPO According to the company,
the LLT-BMT1 is imprinted with
CooperVision Specialty EyeCare has recently introduced bimatoprost (a US Food and
Optimized Pupil Optics (OPO) for its Onefit MED and Onefit Drug Administration (FDA)-
MED+ scleral contact lenses to eye care practitioners (ECPs) in cleared drug, using MediPrint’s
the United States and Canada. proprietary process. It was
administered to five patients,
As per a press release, the new high precision design average age 77.4 years old, who
option − which is supported by a user-friendly online fitting had not previously worn contact
tool − enables ECPs to reposition the multifocal optics to align lenses, in the SIGHT study. The
with the visual axis, a necessary aspect if one wants to get participants wore an LLT-BMT1
superior results and subjective vision. lens in each eye for seven days
The OPO lenses incorporate several markings, including continuously.
a six o’clock dot indication to help patients orient the lens The researchers reported that
correctly on their eye, a circle of eight small dots at 6 mm to the treatment demonstrated
indicate the new centre of the optics for pupil centration, plus 100 percent tolerability, with no
toric hash marks notating the flat meridian as seen in other significant adverse events seen.
Onefit MED toric haptic designs. They also said that the incidence
“The shape of a patient’s sclera − paired with the tension of hyperaemia in SIGHT-1 was
of their eyelids − can often cause scleral lenses to decenter lower than that observed for
down and out. This moves the optics out of ideal alignment bimatoprost drops, one of
and impacts their quality of vision, including creating higher- the standard care treatments
order aberrations for multifocal wearers,” said Justine Siergey, for glaucoma and ocular
OD, FSLS, Manager of Professional Affairs – Irregular Cornea at hypertension. Furthermore, the
CooperVision Specialty EyeCare. “With the new Optimized Pupil study also indicated efficacy
Optics’ design option, practitioners are able to dramatically from a single dose, which was
improve the patient’s visual outcomes and their satisfaction.” not a planned endpoint of the
study design.
“However, this indicator
DRUG-ELUTING CONTACT LENS encourages the company to
FOR GLAUCOMA SHOW POTENTIAL proceed swiftly with SIGHT-2, a
phase 2b dose-ranging clinical
study intended to optimise
MediPrint Ophthalmics, an emerging San Diego-based clinical dosage for efficacy,” the
stage eye care pharmaceutical company, reveals that it’s Sustained company said.
Innovative Glaucoma and Ocular Hypertension Treatment (SIGHT-1)
clinical trial showed a favourable safety and tolerability profile “We are encouraged by the
and demonstrated single dose efficacy of the LLT-BMT1 drug- results of the SIGHT-1 study
eluting contact lens to treat mild to moderate glaucoma or ocular because they validated the
hypertension. MediPrint process and contact
lenses for treating human
As per a press release from the company, SIGHT-1 evaluated subjects, allowing our company
the Company’s lead asset, a unique and complete glaucoma to advance a number of assets
treatment, in human eyes for the first time.
in our pipeline to help protect
“I was excited to study this investigational treatment and sight for patients suffering
believe that LLT-BMT1’s unique product presentation and potential from conceivably disabling eye
benefits differentiate it from other glaucoma diseases like glaucoma,” said
treatments currently on the market,” David Wirta, MD, medical Dan Meyers, CEO of MediPrint
director of the Eye Research Foundation and principal Ophthalmics, in the release.

| NOV-DEC 2021 | 26 CONTACT LENS NEWS